Non-invasive X-ray micro-computed tomographic evaluation of indomethacin on urethane-induced lung carcinogenesis in mice

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4773-4780

  Ueno, Toshiya ^a,b   Imaida, Katsumi ^c   Yoshimoto, Mitsuyoshi ^a   Hayakawa, Takuya ^a,b   Takahashi, Mami ^a   Imai, Toshio ^a   Yanaka, Akinori ^b,d   Tsuta, Koji ^e   Komiya, Masami ^a   Wakabayashi, Keiji ^a,f   Mutoh, Michihiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

A J mouse; Indomethacin; Lung carcinogenesis; Micro CT; Urethane

Indexed keywords

CYCLOOXYGENASE 2; INDOMETACIN; URETHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CHEMOPROPHYLAXIS; CLARA CELL; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DRUG RESPONSE; HISTOPATHOLOGY; HYPERPLASIA; IMAGE RECONSTRUCTION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; LUNG CARCINOGENESIS; LUNG HYPERPLASIA; LUNG TUMOR; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; UPREGULATION;

ADENOCARCINOMA; ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENS; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INDOMETHACIN; LUNG; LUNG NEOPLASMS; MALE; MICE; PRECANCEROUS CONDITIONS; URETHANE; X-RAY MICROTOMOGRAPHY;

EID: 84872662396     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics 2005. CA Cancer J Clin 55: 10-30, 2005.
2. Thun MJ, Namboodiri MM and Heath CW Jr.: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
3. Akasu T, Yokoyama T, Sugihara K, Fujita S, Moriya Y and Kakizoe T: Peroral sustained-release indomethacin treatment for rectal adenomas in familial adenomatous polyposis: A pilot study. Hepatogastroenterology 49: 1259-1261, 2002.
4. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G and Schilsky R: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890, 2003.
5. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F and van Stolk RU: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899, 2003.
6. Reddy BS: Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen 44: 26-35, 2004.
7. Bauer AK, Malkinson AM and Kleeberger SR: Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: genetic similarities. Am J Physiol Lung Cell Mol Physiol 287:L685-703, 2004.
8. Moysich KB, Menezes RJ, Ronsani A, Swede H, Reid ME, Cummings KM, Falkner KL, Loewen GM and Bepler G: Regular aspirin use and lung cancer risk. BMC Cancer 2: 31, 2002.
9. Moody TW, Leyton J, Zakowicz H, Hida T, Kang Y, Jakowlew S, You L, Ozbun L, Zia H, Youngberg J and Malkinson A: Indomethacin reduces lung adenoma number in A/J mice. Anticancer Res 21: 1749-1755, 2001.
10. Vane JR, Bakhle YS and Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120, 1998.
11. Hori Y, Takasuka N, Mutoh M, Kitahashi T, Kojima S, Imaida K, Suzuki M, Kohara K, Yamamoto S, Moriyama N, Sugimura T and Wakabayashi K: Periodic analysis of urethane-induced pulmonary tumors in living A/J mice by respiration-gated X-ray microcomputed tomography. Cancer Sci 99: 1774-1777, 2008.
12. Niho N, Mutoh M, Komiya M, Ohta T, Sugimura T and Wakabayashi K: Improvement of hyperlipidemia by indomethacin in Min mice. Int J Cancer 121: 1665-1669, 2007.
13. Ulrich M: International Classification of Rodent Tumors: Mouse. New York: Springer-Verlag, 2001.
14. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Hirohashi S, Kondo H and Shimosato Y: Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75: 2844-2852, 1995.
15. Festing MF, Lin L, Devereux TR, Gao F, Yang A, Anna CH, White CM, Malkinson AM and You M: At least four loci and gender are associated with susceptibility to the chemical induction of lung adenomas in A/J x BALB/c mice. Genomics 53: 129-136, 1998.
16. Gariboldi M, Manenti G, Canzian F, Falvella FS, Radice MT, Pierotti MA, Della Porta G, Binelli G and Dragani TA: A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6. Nat Genet 3: 132-136, 1993.
17. Manenti G, Gariboldi M, Elango R, Fiorino A, De Gregorio L, Falvella FS, Hunter K, Housman D, Pierotti MA and Dragani TA: Genetic mapping of a pulmonary adenoma resistance (Par1)in mouse. Nat Genet 12: 455-457, 1996.
18. Pataer A, Nishimura M, Kamoto T, Ichioka K, Sato M and Hiai H: Genetic resistance to urethan-induced pulmonary adenomas in SMXA recombinant inbred mouse strains. Cancer Res 57:2904-2908, 1997.
19. Lin L, Festing MF, Devereux TR, Crist KA, Christiansen SC, Wang Y, Yang A, Svenson K, Paigen B, Malkinson AM and You M: Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene. Exp Lung Res 24: 481-497, 1998.
20. Miyashita N and Moriwaki K: H-2-controlled genetic susceptibility to pulmonary adenomas induced by urethane and 4-nitroquinoline 1-oxide in A/Wy congenic strains. Jpn J Cancer Res 78: 494-498, 1987.
21. Dihlmann S, Klein S and Doeberitz Mv MK: Reduction of beta-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin. Mol Cancer Ther 2: 509-516, 2003.
22. Tegeder I, Pfeilschifter J and Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057-2072, 2001.
23. Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H and Tarnawski AS: PGE2 stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 286: 923-928, 2001.
24. Uefuji K, Ichikura T and Mochizuki H: Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 6: 135-138, 2000.
25. Rozic JG, Chakraborty C and Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93: 497-506, 2001.